OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
January 18, 2023 07:30 ET
|
OpGen, Inc.
Preliminary full year revenue for 2022 of approximately $ 2.7 million is within most recent guidance rangeCash position as of December 31, 2022 was approximately $7.4 millionBalance sheet strengthened...
OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project
January 17, 2023 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Announces Closing of $7.5 Million Public Offering
January 11, 2023 16:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Jan. 11, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Announces Pricing of $7.5 Million Public Offering
January 06, 2023 20:00 ET
|
OpGen, Inc.
ROCKVILLE, Md., Jan. 06, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Announced 1-for-20 Reverse Stock Split
January 04, 2023 16:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel
December 13, 2022 07:30 ET
|
OpGen, Inc.
Study has enrolled over 1,800 patient samples at 4 U.S. clinical trial sitesPrimary endpoint for Unyvero UTI for urinary tract infection shows overall weighted average sensitivity of 96.4% and overall...
OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 16:10 ET
|
OpGen, Inc.
Completes first two commercial customer installations for Acuitas AMR Gene PanelOpGen subsidiary, Curetis, signed collaboration agreement with BioVersys AG and R&D collaboration agreement with...
OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update
October 27, 2022 07:30 ET
|
OpGen, Inc.
Preliminary Total Revenue for Q3 2022 was approximately $0.4 millionCash as of September 30, 2022 was approximately $10.3 million and as of October 3, 2022 was approximately $13.3 millionAdditional...
OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time
October 27, 2022 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter...
OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support
October 25, 2022 07:30 ET
|
OpGen, Inc.
Unyvero platform for rapid diagnostics to be used in Phase II clinical trial of BV100Focus on the detection of pneumonia patients infected with Acinetobacter baumannii ROCKVILLE, Md. and BASEL,...